hsn
.pdfДиагностика и лечение ХСН
307. |
Al Khadra AS, Salem DN, Rand WM et al. Warfarin anticoagulation |
331. |
Singh SN, Poole J, Anderson J et al. Role of amiodarone or implantable |
|
and survival: a cohort analysis from the Studies of Left Ventricular |
|
cardioverter/defibrillator in patients with atrial fibrillation and heart failure. |
|
Dysfunction. J Am Coll Cardiol. 1998;31 (4):749–753. |
|
Am Heart J. 2006;152 (5):974. e7–11. |
308. |
Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral |
332. |
Kovoor P, Eipper V, Byth K et al. Comparison of sotalol with |
|
anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel |
|
amiodarone for long-term treatment of spontaneous sustained |
|
Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): |
|
ventricular tachyarrhythmia based on coronary artery disease. Eur |
|
a randomised controlled trial. Lancet. 2006;367 (9526):1903–1912. |
|
Heart J. 1999;20 (5):364–374. |
309. |
Cleland JG, Coletta AP, Lammiman M et al. Clinical trials update from the |
333. |
Беленков Ю.Н., Сангонова Д.Ф., Агеев Ф.Т., Мареев В.Ю. Сравни- |
|
European Society of Cardiology meeting 2005: CARE–HF extension |
|
тельное исследование длительного применения соталола, метопроло- |
|
study, ESSENTIAL, CIBIS–III, S–ICD, ISSUE–2, STRIDE–2, SOFA, |
|
ла и амиодарона у больных с тяжелой сердечной недостаточностью |
|
IMAGINE, PREAMI, SIRIUS–II and ACTIVE. Eur J Heart Fail. 2005;7 |
|
и прогностически опасными желудочковыми нарушениями ритма |
|
(6):1070–1075. |
|
сердца. Кардиология, 1996;36 (1):37–48. |
310. |
HylekEM,GoAS,ChangYetal.EffectofIntensityofOralAnticoagulation |
334. |
MacNeil JH. Review of Sotalol safety in 3257 patients with arrhythmias after |
|
on Stroke Severity and Mortality in Atrial Fibrillation. N Engl J Med. |
|
15 June. 1991. Bristol Myers Squibb report, 1993. Data on file. |
|
2003;349 (11):1019–1026. |
335. |
Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N Engl |
311. |
Baker DW, Wright RF. Management of heart failure, IV: anticoagulation |
|
J Med. 1999;341 (12):910–911. |
|
for patients with heart failure due to left ventricular systolic dysfunction. |
336. |
Dries DL, Exner DV, Gersh BJ et al. Atrial fibrillation is associated |
|
JAMA. 1994;272 (20):1614–1618. |
|
with an increased risk for mortality and heart failure progression in patients |
312. |
Dries DL, Domanski MJ, Waclawiw MA et al. Effect of antithrombotic |
|
with asymptomatic and symptomatic left ventricular systolic dysfunction: a |
|
therapy on risk of sudden coronary death in patients with congestive heart |
|
retrospective analysis of the SOLVD trials: Studies of Left Ventricular |
|
failure. Am J Cardiol. 1997;79 (7):909–913. |
|
Dysfunction. J Am Coll Cardiol. 1998;32 (3):695–703. |
313. |
Singer DE, Chang Y, Fang MC et al. Should Patient Characteristics |
337. |
Pardaens K, Van Cleemput J, Vanhaecke J, Fagard RH. Atrial fibrillation is |
|
Influence Target Anticoagulation Intensity for Stroke Prevention |
|
associated with a lower exercise capacity in male chronic heart failure |
|
in Nonvalvular Atrial Fibrillation?: The ATRIA Study. Circ Cardiovasc |
|
patients. Heart. 1997;78 (6):564–568. |
|
Qual Outcomes. 2009;2 (4):297–304. |
338. |
Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for |
314. |
Carson P, Ziesche S, Johnson G, Cohn JN, for the Vasodilator-Heart |
|
the management of patients with atrial fibrillation. A report of the American |
|
Failure Trial Study Group. Racial differences in response to therapy for |
|
College of Cardiology/American Heart Association Task Force on Practice |
|
heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. |
|
Guidelines and the European Society of Cardiology Committee for Practice |
|
1999;5 (3):178–187. |
|
Guidelines and Policy Conferences (Committee to develop guidelines for the |
315. |
Шарашидзе М.Л., Мареев В.Ю., Суворов Ю.И. и др. Влияние изо- |
|
management of patients with atrial fibrillation) developed in collaboration |
|
сорбида динитрата на водные пространства организма при хрони- |
|
with the North American Society of Pacing and Electrophysiology. Eur |
|
ческой недостаточности кровообращения. Тер. архив. 1989;61 |
|
Heart J. 2001;22 (20):1852–1923. |
|
(6):119–122. |
339. |
Wyse DG, Waldo AL, DiMarco JP et al. The Atrial Fibrillation Follow-up |
316. |
Packer M, O’Connor CM, Ghali JK et al. Effect of amlodipine on |
|
Investigation of Rhythm Management (AFFIRM) Investigators. A |
|
morbidity and mortality in severe chronic heart failure. Prospective |
|
comparison of rate control and rhythm control in patients with atrial |
|
Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. |
|
fibrillation. N Engl J Med. 2002;347 (23):1825–1833. |
|
1996;335 (15):1107–1114. |
340. |
Van Gelder IC, Hagens VE, Bosker HA et al. Rate Control versus Electrical |
317. |
O’Connor CM, Carson PE, Miller AB et al. Effect of amlodipine on mode |
|
Cardioversion for Persistent Atrial Fibrillation (RACE) Study Group. N Engl |
|
of death among patients with advanced heart failure in the PRAISE trial. |
|
J Med. 2002;347 (23):1834–1840. |
|
Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol. |
341. |
Boos CJ, Carlsson J, More RS. Rate or rhythm control in persistent atrial |
|
1998;82 (7):881–887. |
|
fibrillation? QJM. 2003;96 (12):881–892. |
318. |
Kanel WB, Plehn JF, Cupples LA. Cardiac failure and sudden death |
342. |
Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest |
|
in the Framingham Study. Am Heart J. 1988;115 (4):869–875. |
|
effective intensity of prophylactic anticoagulation in for patients with |
319. |
Luu M, Stevenson WG, Stevenson LW et al. Diverse mechanisms |
|
nonrheumatic atrial fibrillation. N Engl J Med. 1996;335 (8):540–546. |
|
of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80 |
343. |
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic treatment |
|
(6):1675–1680. |
|
to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann |
320. |
Мареев В.Ю. Сердечная недостаточность и желудочковые наруше- |
|
Intern Med. 1999;131 (7):492–501. |
|
ния ритма сердца: проблема лечения. Кардиология. 1996;36 (12):4– |
344. |
Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM |
|
12 |
|
substudy of the first antiarrhythmic drug. AFFIRM First Antiarrhythmic |
321. |
Hjalmarson A, Goldstein S, Fagerberg B, et al, for the MERIT–HF Study |
|
Drug Substudy Investigators. J Am Coll Cardiol. 2003;42 (1):20–29. |
|
Group. Effects of controlled-release metoprolol on total mortality, |
345. |
Letelier LM, Udol K, Ena J et al. Effectiveness of amiodarone for conversion |
|
hospitalizations, and well-being in patients with heart failure: the |
|
of atrial fibrillation to sinus rhythm. Arch Intern Med. 2003;163 (7):777– |
|
Metoprolol CR/XL Randomized Intervention Trial in congestive heart |
|
785. |
|
failure (MERIT-HF). JAMA. 2000;283 (10):1295–302. |
346. |
Naccarelli GV, Rinkenberger RL, Dougherty AH, Fitzgerald DM. Adverse |
322. |
Poole-Wilson PA, Uretsky BF, Thygesen K et al. Mode of death in heart |
|
effects of amiodarone: pathogenesis, incidence and management. Med |
|
failure: findings from the ATLAS trial. Heart. 2003;89 (1):42–48. |
|
Toxicol Adverse Drug Exp. 1989;4 (4):246–253. |
323. |
Казей Д.В., Мареев В.Ю., Мухарлямов Н.М. Влияние изменений |
347. |
Greene HL, Graham EL, Werner JA et al. Toxic and therapeutic effects |
|
гемодинамики на нарушения ритма сердца: опыт длительного внут- |
|
of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol. |
|
ривенного введения раствора нитроглицерина больным с сердечной |
|
1983;2 (6):1114–1128. |
|
недостаточностью. Бюлл. Всесоюзн. кардиол. научн. Центра. |
348. |
Roy D, Talajic M, Dorian P, Connolly S et al. Amiodarone to prevent |
|
1989;2:20–25. |
|
recurrence of atrial fibrillation. Canadian Trial of atrial Fibrillation |
324. |
Казей Д.В., Мареев В.Ю., Агеев Ф.Т. и др. Влияние периферических |
|
Investigators. N Engl J Med. 2000;342 (13):913–920. |
|
вазодилататоров на нарушения ритма сердца у больных с хроничес- |
349. |
Lundstrom T, Ryden L. Chronic atrial fibrillation. Long-term results of direct |
|
кой сердечной недостаточностью. Кардиология. 1992;32, (4):30–34 |
|
current cardioversion. Acta Med Scand. 1988;223 (1):53–59. |
325. |
Myerburg RJ, Mitrani R, Interian A et al. Interpretation of outcomes |
350. |
Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with |
|
of antiarrhythmic clinical trials: design features and population impact. |
|
angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: |
|
Circulation. 1998;97 (15):1514–1521. |
|
a meta-analysis. J Am Coll Cardiol. 2005;45 (11):1832–1839 |
326. |
CIBIS III trial: bisoprolol treatment for CHF leads to 46% reduction |
351. |
Matsuda M, Matsuda Y, Yamagishi T et al. Effects of digoxin, propranolol, |
|
in sudden death after one year. Cardiovasc J S Afr. 2006;17 (5):278. |
|
and verapamil on exercise in patients with chronic isolated atrial fibrillation. |
327. |
Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic |
|
Cardiovasc Res. 1991;25 (6):453–457. |
|
amiodaroneonmortalityafteracuremyocardial infarction and incongestive |
352. |
David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis |
|
heart failure: meta-analysis of individual data from 6500 patients |
|
in the control of heart rate in patients with chronic atrial fibrillation: beneficial |
|
in randomized trials. Lancet. 1997;350 (9089):1417–1424. |
|
effect of an added beta adrenergic blocking agent. Am J Cardiol. 1979;44 |
328. |
Мареев В.Ю. Возможно ли успешное предотвращение внезапной |
|
(7):1378–1382. |
|
смерти у больных с хронической сердечной недостаточностью и дис- |
353. |
Farshi R, Kistner D, Sarma JS et al. Ventricular rate control in chronic atrial |
|
функциейлевогожелудочка.Препаратыилиаппараты?Кардиология. |
|
fibrillation during daily activity and programmed exercise: a crossover open- |
|
2004;42 (12):4–15. |
|
label study of five drug regimens. J Am Coll Cardiol. 1999;33 (2):304–310. |
329. |
Boutitie F, Boissel JP, Connolly SJ et al. Amiodarone Interaction |
354. |
Khand AU, Rankin AC, Martin W et al. Carvedilol alone or in combination |
|
With β-Blockers. Analysis of the Merged EMIAT (European Myocardial |
|
with digoxin for the management of atrial fibrillation in patients with heart |
|
Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone |
|
failure? J Am Coll Cardiol. 2003;42 (11):1944–1951. |
|
Myocardial Infarction Trial) Databases. Circulation. 1999;99 (17):2268– |
355. |
Davie AP, Love MP, McMurray JJ. Even low-dose aspirin inhibits |
|
2275. |
|
arachidonic acid-induced vasodilation in heart failure. Clin Pharmacol Ther. |
330. |
Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable |
|
2000;67 (5):530–537 |
|
cardioverter-defibrillator for congestive heart failure. N Engl J Med. |
356. |
Guazzi M, Pontone G, Agostoni P. Aspirin worsens exercise performance |
|
2005;352 (3):225–237. |
|
and pulmonary gas exchange in patients with heart failure who are taking |
159
Диагностика и лечение ХСН
|
angiotensin-converting enzyme inhibitors. Am |
Heart |
J. 1999;138 |
|
(ФЛАГ, ФАСОН, ФАГОТ). Журнал Сердечная Недостаточность. |
||
|
(2 Pt 1):254–260. |
|
|
|
2003;4 (5):261–265. |
|
|
357. |
Атауллаханова Д.М., Мареев В.Ю. Влияние лазикса на центральную |
382. |
Cleland JGF. The perindopril in elderly people with chronic heart failure |
||||
|
гемодинамику у больных с сердечной недостаточностью. Тер. Арх. |
|
(PEP-CHF) study. Hot Line I Session |
on XVth World Congress |
|||
|
1980;60 (11):109–112. |
|
|
|
of Cardiology, Barcelona, 03 September 2006. |
|
|
358. |
Jhunds PS, Davie AP, McMurray JJ. Aspirin inhibits the acute venodilator |
383. |
Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of |
||||
|
response to furosemide in patients with chronic heart failure. J Am Coll |
|
treatment on left ventricular mass in essential hypertension. Am J Med. |
||||
|
Cardiol. 2001;37 (5):1234–1238. |
|
|
|
2003;115 (1):41–46. |
|
|
359. |
Lindfeld JA, Robertson AD, Lowes BD et al. Aspirin impairs reverse |
384. |
Мареев В.Ю., Овчинников А.Г., Агеев Ф.Т., Беленков Ю.Н. |
||||
|
myocardial remodeling in patients with heart failure treated with beta- |
|
Влияние ингибиторов АПФ и антагонистов рецепторов к ангиотен- |
||||
|
blockers. J Am Coll Cardiol. 2001;38 (7):1950–1956. |
|
|
|
зину-II на диастолическую функцию левого желудочка у пациентов |
||
360. |
A randomized, blinded, trial of clopidogrel vs aspirin in patients at risk of |
|
с относительно сохранной систолической функцией левого желу- |
||||
|
ischemicevents(CAPRIE).CAPRIESteeringCommittee.Lancet.1996;348 |
|
дочка: результаты исследования «Периндоприл, |
ИРбесартан |
|||
|
(9038):1329–1339. |
|
|
|
и АмлодипиН у болЬных с ХСН и сохраненной систолической фун- |
||
361. |
Yusuf S, Zhao F, Mehta S. R et al. Effects of clopidogrel in addition to aspirin |
|
кцией левого желудочка (ПИРАНЬя). Журнал Сердечная |
||||
|
in patients with acute coronary syndromes without ST-segment elevation. N |
|
Недостаточность. 2005;6 (1):4–14. |
|
|
||
|
Engl J Med. 2001;345 (7):494–502. |
|
|
385. |
Bergstrom A, Anersson B, Ender M et al. Effect of carvedilol on diastolic |
||
362. |
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised |
|
function in patients with diastolic heart failure and preserved systolic |
||||
|
trialists of antiplatelet therapy, I: prevention of death, myocardial infarction, |
|
function. Results of the Swedish Doppler-echocardiographic study |
||||
|
and stroke by prolonged antiplatelet therapy in various categories of patients. |
|
(SWEDIC). Eur J Heart Fail. 2004;6 (4):453–461. |
|
|||
|
BMJ. 1994;308 (6921):81–106. |
|
|
386. |
Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the |
||
363. |
Cleland JGF. Aspirin: does it have a role in the treatment of heart failure due |
|
effect of nebivolol on mortality and cardiovascular hospital admission in |
||||
|
to ischemic heart disease? In book.: Coats A. |
(ed) |
Controversies |
|
elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26 |
||
|
in the management of heart failure. Churchill Livingstone. 1997:69–82 |
|
(3):215–225. |
|
|
||
364. |
Hayden M, Pigone M, Phillips et al. Aspirin for primary prevention of |
387. |
The Danish Study Group on Verapamil in Myocardial Infarction. Secondary |
||||
|
cardiovascular events: a summary of the evidence for U.S. Preventive |
|
prevention with verapamil after myocardial infarction. Am J Cardiol. 1990;66 |
||||
|
Services Task Force. Ann Intern Med. 2002;136 (2):161–172 |
|
|
(21):33I–40I. |
|
|
|
365. |
Peterson JG, Topol EJ, Sapp SK et al. Evaluation of the effect of aspirin |
388. |
Lopez B, Querejrta R, Gonzalez A et al. Effects of loop diuretics on |
||||
|
combined with angiotensin-converting enzyme inhibitors in patients |
|
myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am |
||||
|
with coponary artery disease. Am J Med. 2000;109 (5):371–377. |
|
Coll Cardiol. 2004;43 (11):2028–2035. |
|
|
||
366. |
Latini R, Tognioni G, Maggioni AP et al. Clinical effects of early angiotensin- |
389. |
Ali Ahmed, Rich MW, Love TE et al. Digoxin and reduction in mortality and |
||||
|
converting enzyme inhibitor treatment for acute myocardial infarction are |
|
hospitalization in heart failure: a comprehensive post hoc analysis of the DIG |
||||
|
similar in presence ana absence of aspitin: systematic overview of individual |
|
trial. Eur Heart J. 2006;27 (2):178–186. |
|
|
||
|
data from 96712 randomized patients. Angiotensin-converting Enzyme |
390. |
Рекомендации Всероссийского научного общества специалистов |
||||
|
Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol. |
|
по клинической электрофизиологии, аритмологии и кардиостимуля- |
||||
|
2000;35 (7):1801–1807. |
|
|
|
ции по проведению клинических электрофизиологических исследо- |
||
367. |
Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in |
|
ваний, катетерной абляции и имплантации антиаритмических уст- |
||||
|
patients with heart failure or left ventricular dysfunction: a systematic |
|
ройств. http://cardio.tomsk.ru/recom. pdf. |
|
|
||
|
overview of data from individual patients. ACE-inhibitor Myocardial |
391. |
РевишвилиА.Ш.,АнтонченкоИ.В.,АрадашевА.В.идр.Клинические |
||||
|
Infarction Collaborative Group. Lancet. 2000;355 (9215):1575–1581. |
|
Рекомендации по применению электрокардиостимуляторов, имплан- |
||||
368. |
Takkouche, Etminan M, Caamano F et al. Interaction between aspirin |
|
тируемых кардиовертеров-дефибрилляторов, устройств для сердеч- |
||||
|
andACEinhibitors:resolvingdiscrepanciesusingameta–nalysis.Interaction |
|
ной ресинхронизирующей терапии и имплантируемых кардиомони- |
||||
|
between aspirin and ACE Inhibitors: resolving discrepancies using a meta- |
|
торов. ВНОА. Новая редакция. Москва 2009, с. 13–146. |
|
|||
|
analysis. Drug Saf. 2002;25 (5):373–378. |
|
|
392. |
European Heart Rhythm Association; Heart Rhythm Society; Zipes DP, |
||
369. |
Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone |
|
Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 guidelines for |
||||
|
in severe chronic heart failure: results of a multicenter study in the United |
|
management of patients with ventricular arrhythmias and the prevention |
||||
|
States. Am Heart J. 1991;121:1956–1964. |
|
|
|
of sudden cardiac death-executive summary. J Am Coll Cardiol. 2006;48 (5): |
||
370. |
Hatzizacharias A, Makris T, Krespi P et al. Intermittent milrinone effect |
|
e247–346. |
|
|
||
|
on long-term hemodynamic profile in patients with severe congestive heart |
393. |
Bristow M, Saxon L, Boehmer J et al. Comparison of Medical Therapy, |
||||
|
failure. Am Heart J. 1999;138:241–246. |
|
|
|
Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. |
||
371. |
Uretsky BF, Jessup M, Konstam MA et al, for the Enoximone Multicenter |
|
Cardiac-resynchronization therapy with or without an implantable |
||||
|
Trial Group. Multicenter trial of oral enoximone in patients with moderate to |
|
defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May |
||||
|
moderately severe congestive heart failure: lack of benefit compared with |
|
20;350 (21):2140–2150. |
|
|
||
|
placebo. Circulation. 1990;82 (3):774–780. |
|
|
394. |
Cleland J, Daubert J, Erdmann E et al. Cardiac Resynchronization-Heart |
||
372. |
Feldman AM, Bristow MR, Parmley WW et al, for the Vesnarinone Study |
|
Failure (CARE-HF) Study Investigators. The effect of cardiac |
||||
|
Group. Effects of vesnarinone on morbidity and mortality in patients |
|
resynchronization on morbidity and mortality in heart failure. N Engl J Med. |
||||
|
with heart failure. N Engl J Med. 1993;329 (3):149–155. |
|
|
2005;352 (15):1539–1549. |
|
|
|
373. |
Packer M, Carver JR, Rodeheffer RJ et al, for the PROMISE Study |
395. |
Abraham W, Young J, Leon A et al. Multicenter InSync ICD II Study |
||||
|
Research Group. Effect of oral milrinone on mortality in severe chronic heart |
|
Group. Effects of cardiac resynchronization on disease progression in patients |
||||
|
failure. N Engl J Med. 1991;325 (21):1468–1475. |
|
|
|
with left ventricular systolic dysfunction, an indication for an implantable |
||
374. |
Applefeld MM, Newman KA, Sutton FJ et al. Outpatient dobutamine |
|
cardioverter-defibrillator, and mildly symptomatic chronic heart failure. |
||||
|
and dopamine infusions in the management of chronic heart failure: clinical |
|
Circulation. 2004;110 (18):2864–2868. |
|
|
||
|
experience in 21 patients. Am Heart J. 1987;114 (3):589–595. |
|
396. |
Lee D, Green L, Liu P et al. Effectiveness of implantable defibrillators for |
|||
375. |
Elis A, Bental T, Kimchi O, Ravid M, Lishner M. Intermittent dobutamine |
|
preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol. |
||||
|
treatment in patients with chronic refractory congestive heart failure: a |
|
2003;41 (9):1573–1582. |
|
|
||
|
randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther. |
397. |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators |
||||
|
1998;63 (6):682–685. |
|
|
|
in patients resuscitated from near-fatal |
ventricular |
arrhythmias. |
376. |
Caffe MS, Califf RM, Adams KF et al. Short-term intravenous milrinone for |
|
The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. |
||||
|
acute exacerbation of chronic heart failure: a randomized controlled trial. |
|
N Engl J Med. 1997;337 (22):1576–1583. |
|
|
||
|
JAMA. 2002;287 (12):1541–1547. |
|
|
398. |
Kadish A, Dyer A, Daubert J et al. Prophylactic defibrillator implantation in |
||
377. |
Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis |
|
patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350 |
||||
|
and treatment of chronic heart failure. Eur Heart J. 2005;26 (11):1115– |
|
(21):2151–2158. |
|
|
||
|
1140. |
|
|
399. |
Moss A, Hall W, Cannom D et al. Improved survival with an implanted |
||
378. |
Moiseev VS, Poder P, Andrejevs N et al. Safety and efficacy of a novel |
|
defibrillator in patients with coronary disease at high risk for ventricular |
||||
|
calcium sensitizer, levosimendan, in patients with left ventricular failure due |
|
arrhythmia. Multicenter Automatic Defibrillator Implantation Trial |
||||
|
to an acute myocardial infarction. A randomized, placebo-controlled, |
|
Investigators. N Engl J Med. 1996;335 (26) :1933–1940. |
|
|||
|
double-blind study (RUSSLAN). Eur Heart J. 2002;23 (18):1422–1432. |
400. |
Buxton A, Lee K, Fisher J et al. A randomized study of prevention of sudden |
||||
379. |
Диагностика и лечение фибрилляции предсердий. Российские реко- |
|
death in patients with coronary artery disease. Multicenter Unsustained |
||||
|
мендации. Разработаны Комитетом экспертов ВНОК. Москва. 2005. |
|
Tachycardia Trial Investigators. N Engl J Med. 1999;341 (25):1882–1890. |
||||
380. |
Philbin EF, Rocco TA. Use of angiotensin-converting enzyme inhibitors in |
401. |
Moss A, Zareba W, Hall W et al. Prophylactic implantation of a defiblirillator |
||||
|
heart failure with preserved ventricular systolic function. Am Heart J. |
|
in patients with myocardial infarction and reduced ejection fraction. N Engl |
||||
|
1997;134 (2 Pt 1):188–195. |
|
|
|
J Med. 2002;346 (12):877–883. |
|
|
381. |
Карпов Ю.А., Мареев В.Ю., Чазова И.Е. Российские программы |
402. |
Rose EA, Gelijns AC, Moskowitz AJ. Long-term mechanical left ventricular |
||||
|
оценки эффективности лечения фозиноприлом больных с артериаль- |
|
assistance for end-stage heart failure. N Engl J Med. 2001;345 (20):1435– |
||||
|
ной гипертонией и сердечной недостаточностью. Проект ТРИ Ф |
|
1443. |
|
|
160